Another hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds
admin 16th August 2019 Uncategorised 0Two of Roche’s oncology blockbusters, Herceptin and Avastin, are facing dire straits as first-ever biosim competitors have entered the U.S. market. Now, a major insurer is putting its money on the new guys. Amgen’s new guys, to be exact.
More: Another hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds
Source: fierce